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Biomarkers of prognosis and 
efficacy of treatment
Drug discovery is protracted, risky and 
costly
Nothing new to offer at the 
patients and the OA research 
community
The Gold Standard 
(Radiography) is inadequate
…We need better methods to predict OA 
progression and response to therapy 
Slide courtesy of Dr A Mobasheri (Nottingham University)
The main limitations of JSN 
 Indirect measure of the alteration in 
articular cartilage.
 Fails to measure a dynamic process
 Confounded by the presence of 
meniscal lesions and extrusion.
 Changes overtime are small, and occur 
in only a subset (progressors) of patients.
 Poorly reproducible (full extension).
















Soluble or « wet » biomarkers « Dry » biomarkers
A biomarker is a characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a 
therapeutic intervention. » 
Biomarkers Definitions Working Group I. Biomarkers and surrogate endpoints: preferred definitions
and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
Womac Lequesne






































































































Bauer et al. Osteoarthritis Cart 2006
• Biomarker associated with extent of severity of OABurden of disease
• Biomarker not yet meeting criteria for another
categoryInvestigative
• Predicts incidence of progression of disease or 
likelihood of response to a treatmentPrognostic
• Indicative of treatment efficacy and for which the 
magnitude of the change is considered pertinent to 
the response. 
Efficacy of treatment
• Dissociate diseased from non-diseased.Diagnostic
• Identify adverse effects and provide means of 
safety.oneSafety
Efficacy of intervention
« Indicative or predictive of 
treatment efficacy and for 
which the magnitude of the 
change is considered
pertinent to the response. »
Biomarkers of efficacy of treatment (BIPEDS)
Updated Van Spil et al.2010
BIPEDS Biomarkers
Efficacy of intervention uCTX-II, sColl2-1,sCOll2-1NO2, sC2C, 
sCOMP, sKS, sYLK40, sPIIANP, uNTX-
I, sOC,  sHA, sMMP-3, sCRP
« Biochemical marker concentration 
differed statistically significantly
between patient populations  with or 
without treatment, or before and 
after treatment within patient »
Levels of qualification of biomarkers for drug
development use






sC2C, sHA, NTX-1, Coll2-1, 
Coll2-1NO2
Exploratory
COMP, C1,2C, CTX-1, CS846
« To qualify for the efficacy of 
intervention category, a marker 
must demonstrate a statistically 
significant relationship between 
treatment-related changes in a 
biomarker and the clinical or 
imaging outcome” 















Richette, Roux Osteoporosis Int 2012
u CTX-II reflects
bone rather than cartilage
metabolism
van Spil W E et al. Ann Rheum Dis 2013
BIOVISCO study: Study design






1NO2, s C2C, sCOMP, 
sCS-846, sCPII,CTX-II
Henrotin Y et al. Journal of Orthopaedic Research
19 FEB 2013
BIOVISCO study
An open label observational prospective study
Conrozier et al, J Orthp Res, 2012; Henrotin et al, J Orthp Res,2013.
D1 
(after the last injection)
90 days
(after the last injection)
p-Value
D1 vs D90
sColl2-1 (nM) 140.34(882.44-285.32) 128.41 (85.6-241.34) 0.05*
sColl2-1NO2 (nM) 0.400 (0.050-1.010) 0.370 (0.14-0.870) 0.025*
uCTX-II (ng/nmolcreat) 392.7 (90.0-816.4) 306.0 (90-1123.9) 0.02*
sPIICP (ng/ml) 817.9 (131.4-1848.6) 874.8.3 (326.4-1435.0) 0.41
sC2C (ng/ml) 223.6 (99.4-329) 209.5 (135.9-291.7) 0.11
sCOMP (U/L) 10.9 (6.0-20.2) 10.5 (6.0-20.0) 0.82
sCS846 (ng/ml) 99.8 (45.9-172.3) 102.2 (53.0-190) 0.38
sHA (ng/ml) 34.1 (15.4-211) 33.3 (9.5-230.1) 0.38
 45 patients with unilateral symptomatic tibiofemoral and/or patellofemoral OA
 3-weekly intraarticular injection of hyalan G20 (Synvisc®)
 Follow-up D1, D30 and D90 after the last injection
16
Coll2-1 and Coll2-1NO2: 










 Specific of degradated cartilage






Only sColl2-1 was significantly decreased 30 days after final injection
Only uCTX-II variation correlated with clinical response (walking pain decrease)
uCTX, sColl2-1 and sHA were independently predictive of clinical response








































Mean values – IC (95%)
MOVES study
CS + GuHCL (Droglican)vsCelecoxib
Preliminary data
 416 knee OA (PP)
 1200 mg CS/1500 GuHCL
 200 mg celecoxib
 6 months treatment
n AGE SEX Weight (Kg) Height (cm)
BMI 
(kg/m2)
celebrex 202 64 (9) 165/37 (82%) 78 (14) 162 (18) 30 (6)
droglican 214 62 (9) 187/27 (87%) 81 (16) 161 (18) 31 (7)
PP 416 63 (9) 352/64 (85%) 80 (15) 162 (18) 30 (6)
Both drugs decreased sColl2-1
Only Droglican decreased significantly Coll2-1









































































Mean values + IC (95%)
MOVES study
CS + GuHCL (Droglican) vs Celecoxib
P value = droglican vs celebrex
 Soluble biomarkers should be included early in the 
development of a drug : « Drug developement 
tool »
→ Preclinical development and phase 1-4 trials
Why?
→ to assist with selection of lead compound
→ to assess safety, mechanism of action, dose finding
and selection, dose reponse profile, enrichment of 
a target population, enrichment for progressors, 
post-marketing safety surveillance
→Companion biomarker (personalized medicine)
Conclusions
Thank you for your attention !
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